---
name: idea-validation
description: |
  ç ”ç©¶å‡èªªé©—è­‰èˆ‡å¯è¡Œæ€§è©•ä¼°æ¡†æ¶ã€‚
  LOAD THIS SKILL WHEN: hypothesisã€å‡èªªã€PICOã€feasibilityã€å¯è¡Œæ€§ã€testableã€å¯é©—è­‰ã€ç ”ç©¶è¨ˆç•«è©•ä¼°ã€check feasibility
  CAPABILITIES: ç´”æŒ‡ä»¤æŠ€èƒ½ï¼Œä¸éœ€è¦å°ˆå±¬ MCP toolã€‚åˆ©ç”¨ LLM æ¨ç†èƒ½åŠ› + ç¾æœ‰ tools (list_saved_references, search_local_references) å®Œæˆåˆ†æã€‚
---

# ç ”ç©¶å‡èªªé©—è­‰èˆ‡å¯è¡Œæ€§è©•ä¼°æŠ€èƒ½

## è¨­è¨ˆæ„åœ–

> **ç‚ºä»€éº¼é€™ä¸æ˜¯ MCP Toolï¼Ÿ**
> PICO åˆ†æã€å‡èªªè©•ä¼°ã€å¯è¡Œæ€§ checklist æ˜¯ã€Œçµæ§‹åŒ–åˆ¤æ–·ã€ï¼ŒLLM æœ¬èº«çš„é†«å­¸çŸ¥è­˜æ¯” regex æ›´æº–ç¢ºã€‚
> Hard-coded regex åš PICO åˆ†æå®¹æ˜“æ¼åˆ¤ï¼Œè€Œ LLM ç†è§£èªæ„èƒ½åšå¾—æ›´å¥½ã€‚

---

## é©ç”¨æƒ…å¢ƒ

| è§¸ç™¼èª | æ“ä½œ |
|--------|------|
| ã€Œæˆ‘çš„å‡èªªæ˜¯å¦ well-formedï¼Ÿã€ | â†’ ä½¿ç”¨ Hypothesis Validation Framework |
| ã€Œé€™å€‹ç ”ç©¶å¯è¡Œå—ï¼Ÿã€ | â†’ ä½¿ç”¨ Feasibility Assessment Framework |
| ã€Œå’Œç¾æœ‰æ–‡ç»æ¯”è¼ƒæœ‰ä»€éº¼å·®ç•°ã€ | â†’ ä½¿ç”¨ `compare_with_literature` MCP toolï¼ˆåˆæ³• toolï¼Œéœ€è¦å­˜å– ref DBï¼‰ |

---

## å¯æ­é…çš„ MCP Tools

| å·¥å…· | ç”¨é€” |
|------|------|
| `compare_with_literature` | å’Œå·²å­˜æ–‡ç»æ¯”è¼ƒç ”ç©¶ idea çš„é‡ç–Šèˆ‡å·®è· |
| `list_saved_references` | æª¢è¦–å·²æ”¶é›†æ–‡ç» |
| `search_local_references` | æœå°‹ç‰¹å®šä¸»é¡Œçš„å·²å­˜æ–‡ç» |
| `validate_concept` | é©—è­‰ concept.md çš„å®Œæ•´æ€§å’Œæ–°ç©æ€§ |
| `validate_for_section` | é‡å°ç‰¹å®š section é©—è­‰æ¦‚å¿µ |

---

## Framework 1: Hypothesis Validation (å‡èªªé©—è­‰)

**ç›®æ¨™**ï¼šè©•ä¼°ç ”ç©¶å‡èªªæ˜¯å¦çµæ§‹å®Œæ•´ã€å¯é©—è­‰

### Step 1: PICO Component Analysis

åˆ†æå‡èªªæ˜¯å¦åŒ…å«å››å€‹æ ¸å¿ƒæˆåˆ†ï¼š

| Component | èªªæ˜ | åµæ¸¬é‡é» |
|-----------|------|----------|
| **P**opulation | ç ”ç©¶å°è±¡ | patients, subjects, adults, children, elderly, ICU, surgical, etc. |
| **I**ntervention | ä»‹å…¥æªæ–½ | treatment, therapy, intervention, drug, procedure, administration, etc. |
| **C**omparison | å°ç…§çµ„ | compared, versus, vs, placebo, standard, conventional, control, etc. |
| **O**utcome | çµæœæŒ‡æ¨™ | outcome, mortality, survival, recovery, length of stay, score, rate, etc. |

### Step 2: Testability Assessment

è©•ä¼°å››å€‹é¢å‘ï¼š

1. **Directional Prediction** â€” æ˜¯å¦æœ‰æ–¹å‘æ€§é æ¸¬ï¼Ÿ
   - âœ… åŒ…å«ï¼šhigher, lower, better, worse, increase, decrease, reduce, improve, differ
   - âŒ åªæœ‰æè¿°æ€§ï¼ˆå¦‚ "we will study..."ï¼‰

2. **Comparison Element** â€” æ˜¯å¦æœ‰æ˜ç¢ºæ¯”è¼ƒï¼Ÿ
   - âœ… åŒ…å«ï¼šsignificantly, compared, versus, vs, than, relative
   - âŒ ç¼ºå°‘æ¯”è¼ƒåŸºæº–

3. **Hypothesis Type** â€” æ˜¯ null é‚„æ˜¯ alternativeï¼Ÿ
   - Null: no difference, no association, not associated
   - Alternative: åŒ…å«æ–¹å‘æ€§é æ¸¬ï¼ˆç ”ç©¶å¸¸ç”¨ï¼‰

4. **Specificity** â€” å­—æ•¸è©•ä¼°
   - < 10 wordsï¼šå¤ªæ¨¡ç³Šï¼Œéœ€è¦æ“´å……
   - 10-50 wordsï¼šé©ç•¶
   - \> 50 wordsï¼šéåº¦è¤‡é›œï¼Œè€ƒæ…®æ‹†åˆ†

### Step 3: Study Type Recommendation

æ ¹æ“šå‡èªªå…§å®¹å»ºè­°ç ”ç©¶è¨­è¨ˆï¼š

| å‡èªªç‰¹å¾µ | å»ºè­°è¨­è¨ˆ |
|----------|----------|
| effect of, efficacy, treatment, intervention | RCT (if feasible) or Cohort |
| risk factor, association, associated with | Cohort or Case-Control |
| prevalence, proportion, frequency | Cross-Sectional |
| å…¶ä»– | Cohort (default) |

### è¼¸å‡ºçµæ§‹

```markdown
# ğŸ”¬ Hypothesis Validation

**Hypothesis:** {text}

## 1. PICO Component Analysis
| Component | Status | Detected Elements |
|-----------|--------|-------------------|
| Population | âœ…/âŒ | {elements} |
| Intervention | âœ…/âŒ | {elements} |
| Comparison | âœ…/âŒ | {elements} |
| Outcome | âœ…/âŒ | {elements} |

**PICO Score:** X/4

## 2. Testability Assessment
- âœ…/âŒ Directional prediction
- âœ…/âŒ Comparison element
- â„¹ï¸ Hypothesis type (null/alternative)
- âœ…/âš ï¸ Specificity ({word_count} words)

## 3. Study Type Assessment
**Recommended:** {type}

## 4. Overall Assessment
âœ… Well-formed / âš ï¸ Partially formed / âŒ Needs revision

**Suggestions:**
- {specific improvements}
```

---

## Framework 2: Feasibility Assessment (å¯è¡Œæ€§è©•ä¼°)

**ç›®æ¨™**ï¼šç³»çµ±æ€§è©•ä¼°ç ”ç©¶è¨ˆç•«çš„å¯åŸ·è¡Œæ€§

### Sample Size Quick Assessment

| ç ”ç©¶é¡å‹ | å¸¸è¦‹å•é¡Œ |
|----------|----------|
| Case Report (N â‰¤ 10) | N > 10 å¯èƒ½æ˜¯ case series |
| RCT (N < 30) | è€ƒæ…® pilot study æˆ– crossover design |
| N â‰¥ 100 | å¤§å¤šæ•¸è¨­è¨ˆéƒ½åˆç† |
| å…¶ä»– | éœ€è¦ power analysis æ”¯æŒ |

### Timeline Estimation by Study Type

#### RCT / Original Research
| Phase | Estimated Months |
|-------|------------------|
| Ethics / IRB approval | 2 |
| Recruitment & enrollment | timeline Ã· 3 (min 3) |
| Data collection | timeline Ã· 3 (min 3) |
| Analysis & writing | timeline Ã· 4 (min 2) |

#### Retrospective Study
| Phase | Estimated Months |
|-------|------------------|
| Ethics / IRB approval | 1 |
| Data extraction | 2 |
| Analysis & writing | timeline Ã· 2 (min 2) |

#### Systematic Review
| Phase | Estimated Months |
|-------|------------------|
| Protocol & registration | 1 |
| Systematic search | 2 |
| Screening & extraction | timeline Ã· 3 (min 2) |
| Analysis & writing | timeline Ã· 3 (min 2) |

### ğŸ§  Feasibility Checklist (17 items, 5 categories)

#### Data & Sample
| Item | Importance |
|------|------------|
| Data source identified and accessible | Critical |
| Sample size achievable in timeframe | Critical |
| Inclusion/exclusion criteria defined | High |

#### Ethics & Compliance
| Item | Importance |
|------|------------|
| IRB/Ethics approval plan | Critical |
| Informed consent strategy | Critical |
| Data privacy compliance (GDPR/HIPAA) | High |

#### Resources & Timeline
| Item | Importance |
|------|------------|
| Funding secured or not required | High |
| Research team and roles defined | Medium |
| Timeline realistic for study design | High |
| Equipment and software available | Medium |

#### Methodology
| Item | Importance |
|------|------------|
| Statistical analysis plan drafted | High |
| Primary outcome clearly defined | Critical |
| Validated measurement tools identified | High |
| Confounders identified and plan to address | High |

#### Publication
| Item | Importance |
|------|------------|
| Target journal identified | Medium |
| Reporting guideline identified (CONSORT/STROBE/etc) | Medium |
| Novelty vs existing literature confirmed | High |

### è¼¸å‡ºçµæ§‹

```markdown
# ğŸ“‹ Feasibility Assessment

**Research Plan:** {description}
**Study Type:** {type}
**Sample Size:** {N}
**Timeline:** {months} months

---

## Sample Size Assessment
{assessment based on study type}

## Timeline Assessment
| Phase | Estimated Months |
|-------|------------------|
{phases based on study type}

**Total minimum:** {sum} months
{âš ï¸ if timeline < total_min}

## Feasibility Checklist

### Data & Sample
| Item | Importance | Status |
|------|------------|--------|
{items with â˜ Not assessed}

(repeat for all 5 categories)

---
ğŸ’¡ Mark each as âœ… Met, âš ï¸ Needs Work, or âŒ Blocker.
All 'Critical' items must be âœ… before proceeding.
```

---

## âš ï¸ ä½¿ç”¨åŸå‰‡

1. **PICO åˆ†æç”¨èªæ„ç†è§£** â€” ä¸è¦åªåšé—œéµå­—åŒ¹é…ï¼Œç†è§£ä¸Šä¸‹æ–‡
2. **å¯è¡Œæ€§è©•ä¼°è¦ä¿å®ˆ** â€” å¯§å¯é«˜ä¼°æ™‚é–“ï¼Œä¸è¦ä½ä¼°
3. **å’Œæ–‡ç»æ¯”è¼ƒç”¨ MCP tool** â€” `compare_with_literature` éœ€è¦å­˜å– reference DBï¼Œé€™æ˜¯åˆæ³• tool
4. **æ‰€æœ‰ Critical é …ç›®å¿…é ˆé€šé** â€” åœ¨é–‹å§‹ protocol å‰

---

## ç›¸é—œæŠ€èƒ½

- `concept-development` â€” ç™¼å±•æ¦‚å¿µï¼ˆå‡èªªé©—è­‰çš„å‰ä¸€æ­¥ï¼‰
- `concept-validation` â€” é©—è­‰æ¦‚å¿µæ–°ç©æ€§
- `literature-review` â€” æ‰¾ç›¸é—œæ–‡ç»
- `manuscript-review` â€” æ’°å¯«å¾Œçš„å¯©æŸ¥
